🇺🇸 RCUS — Arcus Biosciences, Inc.

Salud Compra fuerte
← Volver

Precio actual

19,31 USD

Máx. histórico

48,47

1807 días

Caída desde máximo

-60,16%

Rango 52 semanas

17,43 – 31,74

Variación hoy

+2,12%

Cierre anterior

18,91

Rango de hoy

18,60 – 19,61

Volumen hoy

2.076.185

Peor caída histórica

-85,83%

23/11/2021 → 04/04/2025

Aún sin recuperar

Volatilidad anualizada ⓘ

75,61%

Información
Nombre completo
Arcus Biosciences, Inc.
Divisa
USD
Mercado
NYSE
Sector
Salud
Industria
Biotechnology
Empleados
601
PER ⓘ
—
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
41,00 USD (puede no estar actualizado)
Primera cotización
15/03/2018
Precio actualizado
hace 13 horas
Sobre la empresa

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC; BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases; and Bristol-Myers Squibb Company to develop a novel treatment regimen that delivers tumor control in kidney cancer. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.

Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
14/08/2023 18,17 18,35 17,65 18,03 -0,99% 3,85% 463.200
11/08/2023 18,34 18,82 18,19 18,21 -1,25% 3,44% 420.600
10/08/2023 17,89 18,48 17,89 18,44 +2,22% 3,30% 494.900
09/08/2023 18,64 18,76 17,94 18,04 -2,17% 4,43% 661.500
08/08/2023 18,06 18,55 17,73 18,44 +1,26% 4,54% 993.400
07/08/2023 19,31 19,36 18,09 18,21 -4,26% 6,55% 669.100
04/08/2023 19,05 19,32 18,91 19,02 -0,05% 2,15% 472.400
03/08/2023 19,20 19,37 18,96 19,03 -0,57% 2,14% 432.100
02/08/2023 19,19 19,34 18,76 19,14 -1,90% 3,02% 603.100
01/08/2023 19,60 19,72 19,17 19,51 -1,96% 2,78% 540.000
31/07/2023 19,99 20,17 19,41 19,90 +0,00% 3,80% 439.500
28/07/2023 19,78 20,64 19,60 19,90 +2,05% 5,26% 818.400
27/07/2023 19,50 19,90 19,19 19,50 +0,31% 3,64% 812.900
26/07/2023 19,38 19,97 19,10 19,44 +0,83% 4,49% 912.100
25/07/2023 19,47 19,72 19,15 19,28 -1,13% 2,93% 1.000.800
24/07/2023 19,81 19,90 19,39 19,50 -2,69% 2,57% 646.200
21/07/2023 19,81 20,10 19,51 20,04 +2,04% 2,98% 653.800
20/07/2023 19,80 20,14 19,36 19,64 -0,66% 3,94% 623.300
19/07/2023 20,24 20,66 19,69 19,77 -3,14% 4,79% 909.500
18/07/2023 21,85 21,91 20,34 20,41 -6,07% 7,19% 709.200
17/07/2023 21,95 22,38 21,53 21,73 -0,78% 3,87% 622.500
14/07/2023 22,64 22,85 21,74 21,90 -3,44% 4,88% 559.600
13/07/2023 23,70 23,72 22,23 22,68 -3,65% 6,27% 953.100
12/07/2023 23,08 24,17 22,88 23,54 +3,88% 5,59% 1.727.200
11/07/2023 21,90 23,13 21,90 22,66 +3,56% 5,62% 1.366.800
10/07/2023 20,40 21,90 20,35 21,88 +7,41% 7,60% 950.600
07/07/2023 20,66 21,04 20,31 20,37 -1,45% 3,56% 543.800
06/07/2023 20,27 21,24 20,11 20,67 +0,00% 5,56% 1.689.300
05/07/2023 20,58 20,88 20,38 20,67 +1,13% 2,45% 658.800
03/07/2023 20,41 20,95 20,06 20,44 +0,64% 4,36% 423.600